| | For Immediate Release January 5, 2022
Contact: /Elizabeth Goodsitt/Jennifer Miller 608-266-1683 Wisconsin Receives Oral Antiviral COVID-19 Treatments Initial supply of molnupiravir and Paxlovid is limited, both drugs require a prescription The Wisconsin Department of Health Services (DHS) announced today that they have received the first allocation of oral antiviral COVID-19 treatments molnupiravir and Paxlovid to treat patients diagnosed with mild to moderate COVID-19. The initial supply available to states from the federal government is extremely limited. Under guidance developed by the National Institutes of Health, health care providers are encouraged to prioritize prescribing these new therapeutics to those patients at greatest risk of serious illness or hospitalization from COVID-19. Wisconsinites who may be eligible for these treatments should talk with their health care provider. "While these new antiviral pills may help treat COVID-19, it's important to remember these drugs are not a substitution for protecting yourself by getting vaccinated and wearing a mask in public places," said DHS Secretary-designee Karen Timberlake. "We anticipate high demand for these medications, and we know that the initial supply we are receiving will be extremely limited. Please be patient as providers will prioritize people at highest risk for developing serious illness from the virus. We are committed to distributing these pills equitably across the state, and access will increase as Wisconsin receives more allocations from the federal government." View the entire news release. | | | |
No comments:
Post a Comment